Amendments to the Claims

The listing of claims below replaces all prior versions, and listings, of claims in the subject application:

Claims 1-41. (Canceled)

42. (Previously presented) A method for treating a subject afflicted with a disease associated with an A_1 adenosine receptor in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound having the structure:



or



or a pharmaceutically acceptable salt thereof so as to thereby treat the subject, wherein the disease is antidiuresis, bradycardia, bronchitis, bronchoconstriction, Alzheimer's disease, cardiac arrythmias, cardiac hypoxia, congestive heart failure, hypertension, inflammation, negative cardiac inotropy and dromotropy, renal failure, sedation or is associated with transmitter release, respiratory epithelia, contraction of smooth muscle underlying respiratory epithelia, vasoconstriction or mast cell degranulation.

43. (Previously presented) The method of claim 42, wherein the subject is a mammal.

44. (Previously presented) The method of claim 43, wherein the mammal is a human.

45. (Previously presented) The method of claim 42, wherein the disease is congestive heart failure.

46. (Previously presented) A method for inhibiting the activity of an A1 adenosine receptor in a cell, which comprises contacting the cell with a compound having the structure:



or



or a pharmaceutically acceptable salt thereof.

47. (Previously presented) The method of claim 46, wherein the cell is a human cell.

48. (Previously presented) A method for treating a subject having a respiratory disorder associated with the A1 adenosine receptor in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound having the structure:



or



or a pharmaceutically acceptable salt thereof, so as to thereby treat the subject.

49. (Previously presented) The method of claim 48, wherein the respiratory disorder is asthma, chronic obstructive pulmonary disease, allergic rhinitis, or an upper respiratory disorder.

50. (Previously presented) The method of claim 48, wherein the subject is a human.

Claims 51-53. (Canceled)

54. (Previously presented) A pharmaceutical composition comprising a compound having the structure:



or



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

55. (Previously presented) The pharmaceutical composition of claim 54, further comprising at least one of either a steroid, β2 agonist, glucocorticoid, leukotriene antagonist, or an anticolinergic agonist.

56. (Previously presented) The pharmaceutical composition of claim 54, wherein the pharmaceutical composition is formulated for administration as a periocular, retrobulbar or intraocular injection.

57. (Previously presented) The pharmaceutical composition of claim 54, wherein the pharmaceutical composition is formulated for systemic administration.

58. (Previously presented) The pharmaceutical composition of claim 54, wherein the pharmaceutical composition is formulated for administration as a surgical irrigating solution.

59. (Previously presented) A packaged pharmaceutical composition for treating a subject suffering from a disease associated with an A1 adenosine receptor, comprising the pharmaceutical composition of claim 54 and instructions for using the composition for treating the subject.